[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550483":3},{"organization":4,"armGroups":7,"interventions":67,"overallOfficials":165,"centralContacts":169,"locations":175,"responsibleParty":414,"collaborators":173,"id":416,"slug":417,"hasResults":418,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":173,"eligibilityCriteria":422,"healthyVolunteers":418,"sex":423,"minAge":424,"maxAge":173,"enrollmentInfo":425,"targetDuration":173,"studyType":428,"phases":429,"briefSummary":431,"conditions":432,"keywords":436,"overallStatus":178,"whyStopped":173,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":477},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,14,18,22,26,30,36,41,49,53,59],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1","EXPERIMENTAL","PF-07934040 Monotherapy Dose Escalation PF-07934040 monotherapy at prescribed dose and frequency in 28-day cycles",[13],"Drug: PF-07934040",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2a Cohort A1","Monotherapy dose expansion in 2-3L PDAC. PF-07934040 at prescribed dose and frequency in 28-day cycles",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part 2a Cohort B1","Monotherapy dose expansion in 2-3L CRC. PF-07934040 at prescribed dose and frequency in 28-day cycles",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Part 2a Cohort C1","Monotherapy dose expansion in 2-3L NSCLC. PF-07934040 at prescribed dose and frequency in 28-day cycles",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Part 2a Cohort D1","Monotherapy dose expansion in Other Indications. PF-07934040 at prescribed dose and frequency in 28-day cycles",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Part 2b Cohort A2","Combination (PF-07934040 + Gemcitabine + Nab-paclitaxel) dose escalation\u002Fexpansion in 1L PDAC.\n\nPrescribed dose and frequency in 28-day cycles",[13,34,35],"Combination Product: Gemcitabine","Combination Product: Nab-paclitaxel",{"label":37,"type":10,"description":38,"interventionNames":39},"Part 2b Cohort B2","Combination (PF-07934040 + Cetuximab) dose escalation\u002Fexpansion in 2-3L CRC\n\nPrescribed dose and frequency in 28-day cycles",[13,40],"Combination Product: Cetuximab",{"label":42,"type":10,"description":43,"interventionNames":44},"Part 2b Cohort B3","Combination (PF-07934040 + FOLFOX + Bevacizumab) dose escalation\u002Fexpansion in 1L CRC\n\nPrescribed dose and frequency in 28-day cycles",[13,45,46,47,48],"Combination Product: Fluorouracil","Combination Product: Oxaliplatin","Combination Product: Leucovorin","Combination Product: Bevacizumab",{"label":50,"type":10,"description":51,"interventionNames":52},"Part 2b Cohort B4","Combination (PF-07934040 + FOLFOX + Cetuximab) dose escalation\u002Fexpansion in 1L CRC\n\nPrescribed dose and frequency in 28-day cycles",[13,40,45,46,47],{"label":54,"type":10,"description":55,"interventionNames":56},"Part 2b Cohort C2","Combination (PF-07934040 + Pembro or Sasanlimab) dose escalation\u002Fexpansion in 1L NSCLC (TPS ≥ 50%)\n\nPrescribed dose and frequency in 21-day cycles (for pembro) or 28-day cycles (for sasanlimab)",[13,57,58],"Combination Product: Pembrolizumab","Combination Product: Sasanlimab",{"label":60,"type":10,"description":61,"interventionNames":62},"Part 2b Cohort C3","Combination (PF-07934040 + Pembro + Platinum Chemo) dose escalation\u002Fexpansion in 1L NSCLC (any TPS)\n\nPrescribed dose and frequency in 21-day cycles",[13,57,63,64,65,66],"Combination Product: pemetrexed","Combination Product: Cisplatin","Combination Product: Paclitaxel","Combination Product: Carboplatin",[68,75,82,88,94,101,107,116,123,132,138,146,153,160],{"type":69,"name":70,"description":71,"armGroupLabels":72,"otherNames":73},"DRUG","PF-07934040","panKRAS inhibitor",[9,15,19,23,27,31,37,42,50,54,60],[74],"PF-4040",{"type":76,"name":77,"description":78,"armGroupLabels":79,"otherNames":80},"COMBINATION_PRODUCT","Gemcitabine","Chemotherapy (antimetabolite)",[31],[81],"Gemzar",{"type":76,"name":83,"description":84,"armGroupLabels":85,"otherNames":86},"Nab-paclitaxel","Taxane-type Chemotherapy",[31],[87],"Abraxane",{"type":76,"name":89,"description":90,"armGroupLabels":91,"otherNames":92},"Cetuximab","Monoclonal Antibody (EGFR Inhibitor)",[37,50],[93],"Erbitux",{"type":76,"name":95,"description":96,"armGroupLabels":97,"otherNames":98},"Fluorouracil","Part of FOLFOX chemotherapy regimen\n\ncytotoxic chemotherapy (antimetabolite and pyrimidine analog)",[42,50],[99,100],"5-FU","5-fluorouracil",{"type":76,"name":102,"description":103,"armGroupLabels":104,"otherNames":105},"Oxaliplatin","Part of FOLFOX Chemotherapy Regimen\n\nplatinum based compound (alkylating agent)",[42,50],[106],"Eloxatin",{"type":76,"name":108,"description":109,"armGroupLabels":110,"otherNames":111},"Leucovorin","Part of FOLFOX chemotherapy regimen\n\nFolic Acid Analog",[42,50],[112,113,114,115],"Folinic Acid","Wellcovorin","calcium folinate","Leucovorin Calcium",{"type":76,"name":117,"description":118,"armGroupLabels":119,"otherNames":120},"Bevacizumab","VEG-F inhibitor",[42],[121,122],"Zirabev","Avastin",{"type":76,"name":124,"description":125,"armGroupLabels":126,"otherNames":127},"Pembrolizumab","immune checkpoint inhibitor (PD-1 inhibitor)",[54,60],[128,129,130,131],"Pembro","Lambrolizumab","MK-3475","Keytruda",{"type":76,"name":133,"description":134,"armGroupLabels":135,"otherNames":136},"pemetrexed","Can be used in Platinum-based Chemotherapy regimen\n\nAntimetabolite",[60],[137],"Alimta",{"type":76,"name":139,"description":140,"armGroupLabels":141,"otherNames":142},"Cisplatin","Can be used as part of Platinum-based chemotherapy regimen\n\nPlatinum-based antineoplastic (alkylating agent)",[60],[143,144,145],"Platinol","Cisplatinum","neoplatin",{"type":76,"name":147,"description":148,"armGroupLabels":149,"otherNames":150},"Paclitaxel","Can be used in Platinum-based chemotherapy regimen\n\nTaxane",[60],[151,152],"Taxol","Onxol",{"type":76,"name":154,"description":155,"armGroupLabels":156,"otherNames":157},"Carboplatin","Can be used as part of a platinum-based chemotherapy regimen\n\nplatinum containing compound (alkylating agent)",[60],[158,159],"Paraplatin","Stricarb",{"type":76,"name":161,"description":125,"armGroupLabels":162,"otherNames":163},"Sasanlimab",[54],[164],"PF-06081591",[166],{"name":167,"affiliation":5,"role":168},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[170],{"name":167,"role":171,"phone":172,"phoneExt":173,"email":174},"CONTACT","1-800-718-1021",null,"ClinicalTrials.gov_Inquiries@pfizer.com",[176,190,198,207,217,222,232,237,242,247,257,267,277,286,295,304,310,315,321,331,336,346,355,364,374,380,390,403],{"facility":177,"status":178,"city":179,"state":180,"zip":181,"country":182,"countryCode":183,"cosmosGeoPoint":184,"geoPoint":189,"contacts":173},"Highlands Oncology Group, PA","RECRUITING","Fayetteville","Arkansas","72703","United States","US",{"type":185,"coordinates":186},"Point",[187,188],-94.15743,36.06258,{"lat":188,"lon":187},{"facility":177,"status":178,"city":191,"state":180,"zip":192,"country":182,"countryCode":183,"cosmosGeoPoint":193,"geoPoint":197,"contacts":173},"Rogers","72758",{"type":185,"coordinates":194},[195,196],-94.11854,36.33202,{"lat":196,"lon":195},{"facility":199,"status":178,"city":200,"state":180,"zip":201,"country":182,"countryCode":183,"cosmosGeoPoint":202,"geoPoint":206,"contacts":173},"Highlands Oncology Group","Springdale","72762",{"type":185,"coordinates":203},[204,205],-94.12881,36.18674,{"lat":205,"lon":204},{"facility":208,"status":178,"city":209,"state":210,"zip":211,"country":182,"countryCode":183,"cosmosGeoPoint":212,"geoPoint":216,"contacts":173},"City of Hope (City of Hope National Medical Center, City of Hope Medical Center)","Duarte","California","91010",{"type":185,"coordinates":213},[214,215],-117.97729,34.13945,{"lat":215,"lon":214},{"facility":218,"status":178,"city":209,"state":210,"zip":211,"country":182,"countryCode":183,"cosmosGeoPoint":219,"geoPoint":221,"contacts":173},"City of Hope Investigational Drug Service (IDS)",{"type":185,"coordinates":220},[214,215],{"lat":215,"lon":214},{"facility":223,"status":178,"city":224,"state":225,"zip":226,"country":182,"countryCode":183,"cosmosGeoPoint":227,"geoPoint":231,"contacts":173},"University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)","Aurora","Colorado","80045",{"type":185,"coordinates":228},[229,230],-104.83192,39.72943,{"lat":230,"lon":229},{"facility":233,"status":178,"city":224,"state":225,"zip":226,"country":182,"countryCode":183,"cosmosGeoPoint":234,"geoPoint":236,"contacts":173},"University of Colorado Hospital - Anschutz Outpatient Pavilion",{"type":185,"coordinates":235},[229,230],{"lat":230,"lon":229},{"facility":238,"status":178,"city":224,"state":225,"zip":226,"country":182,"countryCode":183,"cosmosGeoPoint":239,"geoPoint":241,"contacts":173},"University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)",{"type":185,"coordinates":240},[229,230],{"lat":230,"lon":229},{"facility":243,"status":178,"city":224,"state":225,"zip":226,"country":182,"countryCode":183,"cosmosGeoPoint":244,"geoPoint":246,"contacts":173},"University of Colorado Hospital",{"type":185,"coordinates":245},[229,230],{"lat":230,"lon":229},{"facility":248,"status":178,"city":249,"state":250,"zip":251,"country":182,"countryCode":183,"cosmosGeoPoint":252,"geoPoint":256,"contacts":173},"Sibley Memorial Hospital","Washington D.C.","District of Columbia","20016",{"type":185,"coordinates":253},[254,255],-77.03637,38.89511,{"lat":255,"lon":254},{"facility":258,"status":178,"city":259,"state":260,"zip":261,"country":182,"countryCode":183,"cosmosGeoPoint":262,"geoPoint":266,"contacts":173},"START Midwest","Grand Rapids","Michigan","49546",{"type":185,"coordinates":263},[264,265],-85.66809,42.96336,{"lat":265,"lon":264},{"facility":268,"status":178,"city":269,"state":270,"zip":271,"country":182,"countryCode":183,"cosmosGeoPoint":272,"geoPoint":276,"contacts":173},"Siteman Cancer Center - St Peters","City of Saint Peters","Missouri","63376",{"type":185,"coordinates":273},[274,275],-90.62651,38.80033,{"lat":275,"lon":274},{"facility":278,"status":178,"city":279,"state":270,"zip":280,"country":182,"countryCode":183,"cosmosGeoPoint":281,"geoPoint":285,"contacts":173},"Siteman Cancer Center - West County","Creve Coeur","63141",{"type":185,"coordinates":282},[283,284],-90.42262,38.66089,{"lat":284,"lon":283},{"facility":287,"status":178,"city":288,"state":270,"zip":289,"country":182,"countryCode":183,"cosmosGeoPoint":290,"geoPoint":294,"contacts":173},"Siteman Cancer Center - North County","Florissant","63031",{"type":185,"coordinates":291},[292,293],-90.32261,38.78922,{"lat":293,"lon":292},{"facility":296,"status":178,"city":297,"state":270,"zip":298,"country":182,"countryCode":183,"cosmosGeoPoint":299,"geoPoint":303,"contacts":173},"Siteman Cancer Center","St Louis","63108",{"type":185,"coordinates":300},[301,302],-90.19789,38.62727,{"lat":302,"lon":301},{"facility":305,"status":178,"city":297,"state":270,"zip":306,"country":182,"countryCode":183,"cosmosGeoPoint":307,"geoPoint":309,"contacts":173},"Barnes-Jewish Hospital","63110",{"type":185,"coordinates":308},[301,302],{"lat":302,"lon":301},{"facility":311,"status":178,"city":297,"state":270,"zip":306,"country":182,"countryCode":183,"cosmosGeoPoint":312,"geoPoint":314,"contacts":173},"Washington University School of Medicine",{"type":185,"coordinates":313},[301,302],{"lat":302,"lon":301},{"facility":316,"status":178,"city":297,"state":270,"zip":317,"country":182,"countryCode":183,"cosmosGeoPoint":318,"geoPoint":320,"contacts":173},"Siteman Cancer Center - South County","63129",{"type":185,"coordinates":319},[301,302],{"lat":302,"lon":301},{"facility":322,"status":178,"city":323,"state":324,"zip":325,"country":182,"countryCode":183,"cosmosGeoPoint":326,"geoPoint":330,"contacts":173},"Duke University Medical Center, lnvestigational Chemotherapy Service","Durham","North Carolina","27710",{"type":185,"coordinates":327},[328,329],-78.89862,35.99403,{"lat":329,"lon":328},{"facility":332,"status":178,"city":323,"state":324,"zip":325,"country":182,"countryCode":183,"cosmosGeoPoint":333,"geoPoint":335,"contacts":173},"Duke University Medical Center",{"type":185,"coordinates":334},[328,329],{"lat":329,"lon":328},{"facility":337,"status":178,"city":338,"state":339,"zip":340,"country":182,"countryCode":183,"cosmosGeoPoint":341,"geoPoint":345,"contacts":173},"University of Cincinnati Medical Center","Cincinnati","Ohio","45219",{"type":185,"coordinates":342},[343,344],-84.51439,39.12711,{"lat":344,"lon":343},{"facility":347,"status":178,"city":348,"state":339,"zip":349,"country":182,"countryCode":183,"cosmosGeoPoint":350,"geoPoint":354,"contacts":173},"Cleveland Clinic Taussig Cancer Center","Cleveland","44195",{"type":185,"coordinates":351},[352,353],-81.69541,41.4995,{"lat":353,"lon":352},{"facility":356,"status":178,"city":357,"state":339,"zip":358,"country":182,"countryCode":183,"cosmosGeoPoint":359,"geoPoint":363,"contacts":173},"West Chester Hospital","West Chester","45069",{"type":185,"coordinates":360},[361,362],-84.40716,39.33172,{"lat":362,"lon":361},{"facility":365,"status":178,"city":366,"state":367,"zip":368,"country":182,"countryCode":183,"cosmosGeoPoint":369,"geoPoint":373,"contacts":173},"Rhode Island Hospital","Providence","Rhode Island","02903",{"type":185,"coordinates":370},[371,372],-71.41283,41.82399,{"lat":372,"lon":371},{"facility":375,"status":178,"city":366,"state":367,"zip":376,"country":182,"countryCode":183,"cosmosGeoPoint":377,"geoPoint":379,"contacts":173},"Miriam Hospital","02906",{"type":185,"coordinates":378},[371,372],{"lat":372,"lon":371},{"facility":381,"status":178,"city":382,"state":383,"zip":384,"country":182,"countryCode":183,"cosmosGeoPoint":385,"geoPoint":389,"contacts":173},"University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":185,"coordinates":386},[387,388],-95.36327,29.76328,{"lat":388,"lon":387},{"facility":391,"status":392,"city":393,"state":394,"zip":395,"country":396,"countryCode":397,"cosmosGeoPoint":398,"geoPoint":402,"contacts":173},"Beijing Cancer hospital","NOT_YET_RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":185,"coordinates":399},[400,401],116.39723,39.9075,{"lat":401,"lon":400},{"facility":404,"status":178,"city":405,"state":173,"zip":406,"country":407,"countryCode":408,"cosmosGeoPoint":409,"geoPoint":413,"contacts":173},"Pan American Center for Oncology Trials, LLC","Rio Piedras","00935","Puerto Rico","PR",{"type":185,"coordinates":410},[411,412],-66.04989,18.39745,{"lat":412,"lon":411},{"type":415,"investigatorFullName":173,"investigatorTitle":173,"investigatorAffiliation":173,"oldNameTitle":173,"oldOrganization":173},"SPONSOR","100550483","phase-1-a-study-to-learn-about-the-study-medicine-pf-07934040-when-given-alone-or-with-other-anti-cancer-therapies-in-people-with-advanced-solid-tumors-that-have-a-genetic-mutation-100550483",false,"NCT06447662","A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene","Inclusion Criteria:\n\n* Histological or cytological diagnosis of advanced, unresectable, and\u002For metastatic or relapsed\u002Frefractory solid tumor.\n\nECOG PS 0 or 1\n\n* Presence of at least 1 measurable lesion based on RECIST version 1.1 that has not been previously irradiated.\n* Documentation of mutated KRAS gene\n\n  1. PDAC, CRC, Other tumor types: Confirmed KRAS mutation, any variant\n  2. NSCLC: Confirmed KRAS mutation, any variant except previously treated G12C. If driver mutation, must have failed precision medicine therapy \\[eg, inhibitors of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and others\\].\n* Part 1 and Part 2a: Participant must have progressed on standard treatment(s) for which no additional, effective therapy is available.\n\n  1. PDAC (2-3L): Participants must have received and radiologically progressed on prior lines of systemic therapy for metastatic pancreatic adenocarcinoma. If participants received prior neoadjuvant or adjuvant chemotherapy and progressed within 6 months of the last dose, then this should be considered as a prior line of systemic therapy.\n  2. NSCLC (2-3L): Participants must have received prior lines of anti-cancer treatment and progressed on at least a platinum-containing chemotherapy regimen or ICI. Participants may have had only one or two prior lines of therapy in the advanced\u002Fmetastatic setting. For participants with EGFR, ALK, or other genomic tumor alterations, participants must have progressed on approved therapy for these alterations.\n  3. CRC (2-3L): Participants must have had one or two prior lines of therapy for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, oxaliplatin, and\u002For irinotecan for one prior treatment, exposure to VEGF\u002FVEGF receptor (VEGFR) inhibitor is optional;\n  4. Other tumors: Participants, in the judgment of the investigator, must have progressed or become intolerant to all available standard therapies, or have refused such therapy.\n* Part 2b:\n\n  1. PDAC (1L) Cohort A2: Participants must not have received prior chemotherapy for metastatic disease. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy. If relapse occurred within 6 months of last dose of adjuvant treatment or neoadjuvant therapy, the participant would be considered 2L, and not 1L.\n  2. CRC (2-3L) Cohort B2: Participants must have had one or two prior systemic treatment regimens for mCRC. For either one or two prior treatments, these regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin; for one prior treatment, exposure to a VEGF\u002FVEGF receptor (VEGFR) inhibitor is optional.\n  3. CRC (1L) Cohort B3\u002FB4: Participants must not have received prior therapy for metastatic disease and not be a candidate for other targeted therapy or immunotherapy. Participant could have received neoadjuvant therapy, adjuvant therapy, or adjuvant chemo-radiotherapy. If relapse occurred within 6 months of last dose of adjuvant or neoadjuvant therapy, then the participant would be considered 2L, and not 1L.\n  4. NSCLC (1L) Cohort C2: Participants must have a TPS ≥50% and must not have received prior systemic treatment setting.\n  5. NSCLC (1L) Cohort C3: Participants with any TPS and must not have received prior systemic treatment setting.\n\nExclusion Criteria:\n\n* Active or history of pneumonitis\u002FILD or pulmonary fibrosis requiring treatment with systemic steroid therapy.\n* Diagnosis of immunodeficiency or an active autoimmune disease that require systemic treatment with chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy in the past 2 years.\n* Sensory peripheral neuropathy ≥Grade 2\n* Active or history of clinically significant gastrointestinal (GI) disease (including but not limited to inflammatory GI disease \\[eg, ulcerative colitis, Crohn's disease, inflammatory bowel disease\\], immune-mediated colitis, peptic ulcer disease, GI bleeding, chronic diarrhea) and other conditions that are unresolved and\u002For may increase the risk associated with study participation or study treatment administration.\n* Active bleeding disorder, including GI bleeding, as evidenced by hematemesis, significant hemoptysis or melena in the past 6 months.\n* Major surgery or completion of radiation therapy ≤4 weeks prior to enrollment\u002Frandomization or radiation therapy that included \\>30% of the bone marrow.\n* Known sensitivity or contraindication to any component of study intervention (PF 07934040, gemcitabine, nab-paclitaxel, cetuximab, bevacizumab, FOLFOX, 5-FU, pembrolizumab, cisplatin, carboplatin, pemetrexed, SHP2 inhibitor(s), cyclin-dependent kinase (CDK) inhibitor(s), antibody drug conjugates (ADCs) or EGFR inhibitor(s)).\n* Hematologic abnormalities.\n* Renal impairment.\n\n  * Hepatic abnormalities.","ALL","18 Years",{"count":426,"type":427},330,"ESTIMATED","INTERVENTIONAL",[430],"PHASE1","The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.\n\nThis study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:\n\n* are advanced (cancer that doesn't disappear or stay away with treatment) and\n* have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers).\n\nThis includes (but limited to) the following cancer types:\n\nNon-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.\n\nColorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control.\n\nPancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels.\n\nAll participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles.\n\nDepending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle.\n\nParticipants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding.\n\nThe study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.\n\nParticipants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.",[433,434,435],"Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung",[433,437,438,439,440,441,442,443,444,434,445,446,447,448,449,450,451,452,435,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467],"Carcinoma, Ductal, Pancreatic","Duct-Cell Carcinoma of the Pancreas","Duct-Cell Carcinoma, Pancreas","Ductal Carcinoma of the Pancreas","Pancreatic Duct Cell Carcinoma","Pancreatic Ductal Carcinoma","pancreatic ductal adenocarcinoma","PADC","Colorectal Cancer","Colorectal Carcinoma","Colorectal Tumors","Neoplasms, Colorectal","Rectal Cancer","Colon Cancer","CRC","MSS CRC","Non-Small Cell Lung Cancer","Non-Small Cell Lung Carcinoma","Non-Small-Cell Lung Carcinoma","Nonsmall Cell Lung Cancer","Lung Cancer","NSCLC","KRAS","KRAS gene mutation","G12C","G12D","G12V","G12R","G12S","G13D","Q61H","2026-04-15",{"date":470,"type":471},"2026-04-20","ACTUAL",{"date":473,"type":471},"2024-06-27",{"date":475,"type":427},"2029-01-18",{"name":5,"class":6},28]